scholarly journals Global metabolite profiling analysis of lipotoxicity in HER2/neu-positive breast cancer cells

Oncotarget ◽  
2018 ◽  
Vol 9 (43) ◽  
pp. 27133-27150 ◽  
Author(s):  
Jan Baumann ◽  
Mostafa Kokabee ◽  
Jason Wong ◽  
Rakshika Balasubramaniyam ◽  
Yan Sun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Metabolite Profiling ◽  
Breast Cancer Cells ◽  
Profiling Analysis ◽  
Global Metabolite Profiling ◽  
Positive Breast Cancer

scholarly journals Aptamer-protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells

2020 ◽  
Vol 590 ◽  
pp. 119963
Author(s):  
Xiangshang Xu ◽  
Li Li ◽  
Xiaolan Li ◽  
Deding Tao ◽  
Peng Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Positive Breast Cancer

scholarly journals A rapid nanobiosensing platform based on herceptin-conjugated graphene for ultrasensitive detection of circulating tumor cells in early breast cancer

2021 ◽  
Vol 10 (1) ◽  
pp. 744-753
Author(s):  
Zahra Rahimzadeh ◽  
Seyed Morteza Naghib ◽  
Esfandyar Askari ◽  
Fatemeh Molaabasi ◽  
Ali Sadr ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cancer Detection ◽  
Breast Cancer Cells ◽  
Graphene Nanosheets ◽  
Her2 Positive ◽  
Promising Candidate ◽  
Graphene Layers ◽  
The Stability ◽  
Positive Breast Cancer

Abstract In this paper, we use a simple and cheap approach for the synthesis of herceptin-conjugated graphene biosensor to detect the HER2-positive breast cancer cells. The bifunctional graphene-herceptin nanosheets are prepared from graphite by a simple ultrasonic-mediated technique. The prepared protein-mediated graphene is fully characterized. The results show the exfoliation of graphene layers in herceptin solution. Moreover, herceptin is effectively conjugated into the surface of graphene nanosheets. The synthesized herceptin-conjugated graphene is applied for breast cancer detection. The linear range of this biosensor is 1–80 cells, which is significant. The biosensor shows an excellent selectivity performance for detection of HER2-positive cancer cells. Likewise, the stability and functionality of the biosensor is about 40 days. Based on the results, this device is a promising candidate for rapid and selective detection of cancer cells.

scholarly journals UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells

2021 ◽  
Author(s):  
Jun Hua ◽  
Zhe Zhang ◽  
Lili Zhang ◽  
Yan Sun ◽  
Yuan Yuan
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Neoadjuvant Therapy ◽  
Needle Biopsy ◽  
Breast Cancer Cells ◽  
Her2 Positive ◽  
Trastuzumab Treatment ◽  
Her2 Positive Breast Cancer ◽  
Trastuzumab Therapy ◽  
Positive Breast Cancer

Abstract Purpose This study aimed to investigate the possibility of UCP-2 inhibitor in reducing acquired resistance of trastuzumab to improve the outcome of patients receiving trastuzumab therapy by exploring the relationship between UCP-2 expression and HER2 signaling pathway and examining whether UCP-2 expression was modulated by trastuzumab treatment. Methods 32 women diagnosed with primary HER2-positive breast cancer were recruited in this study. Needle biopsy was obtained from patients before they received at least four cycles neoadjuvant therapy containing trastuzumab in combination with chemotherapy. Surgical tumor biopsy was obtained during surgical procedure after the neoadjuvant therapy. Levels of HER2 phosphorylation and UCP-2 expression were detected by immunohistochemistry (IHC) and compared between tumor needle biopsy tissue and surgical tumor samples of these patients, as well as in BT474 breast cancer cells before and after trastuzumab treatment. HER2-selective phosphorylation/kinase activity inhibitor ONT-380 was used to identify the correlation between HER2 phosphorylation level and UCP-2 expression. UCP-2 inhibitor Genipin was then used to evaluate the apoptosis index in BT474 cells treated with trastuzumab. Results UCP-2 expression was significantly elevated in surgical tumor samples from breast cancer patients receiving trastuzumab in a neoadjuvant setting. We further confirmed our findings in HER2-positive BT474 cell line and found that trastuzumab treatment induced phosphorylation of HER2 and the overexpression of UCP-2, and the latter can be reversed by HER2 selective kinase inhibitor ONT-380. Moreover, UCP-2 inhibitor Genipin significantly enhanced the proliferation suppression effects of trastuzumab and markedly promoted apoptosis. Conclusion Taken together, our study identified UCP-2 as a novel therapeutic target for HER2 positive breast cancer and UCP-2 inhibitor may have great potential to enhance the response rate and efficacy of trastuzumab therapy.

scholarly journals Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells

2017 ◽  
Vol 50 (6) ◽  
pp. 2221-2228 ◽  
Author(s):  
Martina S.J. Mcdermott ◽  
Alexandra Canonici ◽  
Laura Ivers ◽  
Brigid C. Browne ◽  
Stephen F. Madden ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Dual Inhibition ◽  
Positive Breast Cancer

scholarly journals Spatiotemporal control of estrogen-responsive transcription in ERα-positive breast cancer cells

Oncogene ◽  
2015 ◽  
Vol 35 (18) ◽  
pp. 2379-2389 ◽  
Author(s):  
P-Y Hsu ◽  
H-K Hsu ◽  
T-H Hsiao ◽  
Z Ye ◽  
E Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Spatiotemporal Control ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document